Modality
siRNA
MOA
USP1i
Target
TIM-3
Pathway
Autophagy
AS
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
Oct 2017
→ Feb 2031
Phase 3Current
NCT08623984
1,223 pts·AS
2017-10→2025-06·Active
NCT07664860
205 pts·AS
2024-05→2031-02·Completed
1,428 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-06-0310mo agoPh3 Readout· AS
2025-08-088mo agoConference· AS
2031-02-054.9y awayPh3 Readout· AS
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Active
P3
Complet…
Catalysts
Ph3 Readout
2025-06-03 · 10mo ago
AS
Conference
2025-08-08 · 8mo ago
AS
Ph3 Readout
2031-02-05 · 4.9y away
AS
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08623984 | Phase 3 | AS | Active | 1223 | HbA1c |
| NCT07664860 | Phase 3 | AS | Completed | 205 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |